Cochrane Evidence Synthesis and Methods ►

Immune checkpoint inhibitors (anti PD-1 or anti PD-L1) versus chemotherapy for second- or third-line treatment of metastatic non-small cell lung cancer

To evaluate the effectiveness and safety of immune checkpoint inhibitors (anti PD-1 or anti PD-L1) compared with standard chemotherapy for second- or third-line treatment of metastatic non-small cell lung cancer (NSCLC).

This is a protocol.

Health topics:

Cancer > Lung > General aspects of treatment

Lungs & airways > Lung cancer > General aspects of treatment

Published:

25 April 2017

Authors:

Moraes FY, Perry LA, Penny-Dimri JC, Ramson D, de Castria TB, Bowman RV, Santos FN, Fong KM, Riera R

See the full Review on

the Cochrane Library

►

Was this helpful? Donate.

If you found this evidence helpful, please consider donating to Cochrane. We are a charity that produces accessible evidence to help people make health and care decisions.
Donate
Print
PDF
Citation
Moraes FY, Perry LA, Penny-Dimri JC, Ramson D, de Castria TB, Bowman RV, Santos FN, Fong KM, Riera R. Immune checkpoint inhibitors (anti PD-1 or anti PD-L1) versus chemotherapy for second- or third-line treatment of metastatic non-small cell lung cancer. Cochrane Database of Systematic Reviews 2017, Issue 4. Art. No.: CD012644. DOI: 10.1002/14651858.CD012644